Technical Analysis for ELVN - Enliven Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 18.07 | 1.57% | 0.28 |
ELVN closed up 3.55 percent on Monday, April 29, 2024, on approximately normal volume. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 1.57% | |
| 50 DMA Support | Bullish | 1.57% | |
| Stochastic Buy Signal | Bullish | 1.57% | |
| Strong but Oversold | Other | 1.57% | |
| Wide Bands | Range Expansion | 1.57% | |
| Oversold Stochastic | Weakness | 1.57% | |
| MACD Bearish Centerline Cross | Bearish | 5.18% | |
| Crossed Above 50 DMA | Bullish | 5.18% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 5.18% | |
| Strong but Oversold | Other | 5.18% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | less than a minute ago |
| Up 1% | less than a minute ago |
| Down 1% | about 1 hour ago |
| 20 DMA Resistance | about 21 hours ago |
| 60 Minute Opening Range Breakout | about 23 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Protein Kinase Inhibitor Tyrosine Kinase Receptors Her2 Chronic Myeloid Leukemia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Protein Kinase Inhibitor Tyrosine Kinase Receptors Her2 Chronic Myeloid Leukemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 26.0 |
| 52 Week Low | 9.84 |
| Average Volume | 285,323 |
| 200-Day Moving Average | 15.07 |
| 50-Day Moving Average | 17.13 |
| 20-Day Moving Average | 18.64 |
| 10-Day Moving Average | 17.52 |
| Average True Range | 1.84 |
| RSI (14) | 49.75 |
| ADX | 15.84 |
| +DI | 21.28 |
| -DI | 20.61 |
| Chandelier Exit (Long, 3 ATRs) | 20.48 |
| Chandelier Exit (Short, 3 ATRs) | 21.48 |
| Upper Bollinger Bands | 21.85 |
| Lower Bollinger Band | 15.42 |
| Percent B (%b) | 0.37 |
| BandWidth | 34.53 |
| MACD Line | -0.01 |
| MACD Signal Line | 0.31 |
| MACD Histogram | -0.319 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 21.14 | ||||
| Resistance 3 (R3) | 21.10 | 19.94 | 20.58 | ||
| Resistance 2 (R2) | 19.94 | 19.09 | 19.96 | 20.39 | |
| Resistance 1 (R1) | 18.87 | 18.57 | 19.41 | 18.91 | 20.21 |
| Pivot Point | 17.71 | 17.71 | 17.98 | 17.73 | 17.71 |
| Support 1 (S1) | 16.64 | 16.86 | 17.18 | 16.68 | 15.37 |
| Support 2 (S2) | 15.48 | 16.34 | 15.50 | 15.19 | |
| Support 3 (S3) | 14.41 | 15.48 | 15.00 | ||
| Support 4 (S4) | 14.45 |
